Home
Scholarly Works
Evidence-based Urology: Subgroup Analysis in...
Journal article

Evidence-based Urology: Subgroup Analysis in Randomized Controlled Trials

Abstract

In randomized controlled trials, investigators often explore the possibility that the treatment effects differ between subgroups (eg, women vs men, old vs young, more versus less severe disease). Investigators often inappropriately claim subgroup effects (also called "effect modification" or "interaction") when the likelihood of a true effect modification is low. Criteria for assessing the credibility of subgroup analyses, nicely summarized in a formal Instrument for Assessing the Credibility of Effect Modification Analyses (ICEMAN), include investigator postulation of a priori hypotheses with a specified direction; support from prior evidence; a low likelihood that chance explains the apparent subgroup effect; and only testing a small number of subgroup hypotheses. PATIENT SUMMARY: Randomized clinical trials often use subgroup analyses to explore whether a treatment is more or less effective in a particular patient subgroup (eg, women vs men, old vs young). In this mini-review, we explore the common pitfalls of subgroup analyses.

Authors

Kilpeläinen TP; Tikkinen KAO; Guyatt GH; Vernooij RWM

Journal

European Urology Focus, Vol. 7, No. 6, pp. 1237–1239

Publisher

Elsevier

Publication Date

November 1, 2021

DOI

10.1016/j.euf.2021.10.001

ISSN

2405-4569

Contact the Experts team